Tevogen Bio Holdings Inc. (TVGN)

Tevogen Bio Holdings, Inc. has experienced a significant stock price decline. The company was notified by Nasdaq of non-compliance with the minimum bid price requirement but regained compliance without a reverse stock split. Tevogen Bio Holdings Inc. was included in the Russell 3000® Index and debuted as a public company by ringing the Nasdaq Opening Bell on February 15, 2024. The company has reported positive safety data from its proof-of-concept clinical trial for TVGN 489 and has highlighted its capital efficiency and reduced operating losses.

As a clinical-stage biotechnology company, Tevogen Bio Holdings, Inc. does not currently have commercialized products with established demand seasonality. The company's focus is on the development and clinical progression of its therapies. Any observed seasonal patterns in its stock price do not directly reflect seasonality in demand for its products and services.

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company in the Biotechnology industry, focusing on biological products. The company develops precision T cell therapies for infectious diseases, cancers, and neurological disorders using CD8+ cytotoxic T lymphocytes (CTLs). Its pipeline includes TVGN 489, which has completed Phase 1 clinical trials for Long COVID and acute COVID-19, as well as TVGN 920, TVGN 930, TVGN 960, TVGN 601, and TVGN 116, which are in preclinical trials for various cancers, EBV-associated lymphomas, multiple sclerosis and hepatitis B. The company utilizes its proprietary ExacTcell™ technology platform.

Tevogen Bio Holdings, Inc. is headquartered in Warren, New Jersey, United States. Its primary operational focus is on research and development activities conducted from its U.S. base. Specific details regarding a broader global operational footprint or extensive international market reach for commercialized products are not readily available.

Tevogen Bio Holdings, Inc.'s reputation has been positively influenced by increased institutional ownership and advancements in its artificial intelligence initiatives. Clinical milestones, including the expansion of HLA coverage for its investigational precision T cell therapy for acute and Long COVID, and emphasis on capital efficiency have also contributed positively. Tevogen was also recognized as the highest valued biotech unicorn of 2022 with a $4.2 billion valuation.

The ownership structure of Tevogen Bio Holdings includes institutional, retail, and individual investors. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Geode Capital Management, Llc, and Northern Trust Corp. Institutional ownership has shown significant growth. Insiders hold a substantial portion of the company's stock, with Ryan H. Saadi owning the most shares.